Correlation Between Eli Lilly and Molecular Partners

Can any of the company-specific risk be diversified away by investing in both Eli Lilly and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eli Lilly and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Eli Lilly and and Molecular Partners AG, you can compare the effects of market volatilities on Eli Lilly and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eli Lilly with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eli Lilly and Molecular Partners.

Diversification Opportunities for Eli Lilly and Molecular Partners

-0.24

Correlation Coefficient

Eli Lilly  Molecular Partners

Very good diversification

The 3 months correlation between Eli and Molecular is -0.24. Overlapping area represents the amount of risk that can be diversified away by holding Eli Lilly and and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Eli Lilly is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eli Lilly and are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Eli Lilly i.e., Eli Lilly and Molecular Partners go up and down completely randomly.

Pair Corralation between Eli Lilly and Molecular Partners

Considering the 90-day investment horizon Eli Lilly and is expected to generate 0.51 times more return on investment than Molecular Partners. However, Eli Lilly and is 1.96 times less risky than Molecular Partners. It trades about 0.48 of its potential returns per unit of risk. Molecular Partners AG is currently generating about -0.12 per unit of risk. If you would invest  80,904  in Eli Lilly and on December 4, 2024 and sell it today you would earn a total of  12,068  from holding Eli Lilly and or generate 14.92% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Eli Lilly and  vs.  Molecular Partners AG

Eli Lilly

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Eli Lilly and are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly sluggish essential indicators, Eli Lilly may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Molecular Partners

Risk-Adjusted Performance

Very Weak

Over the last 90 days Molecular Partners AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Eli Lilly and Molecular Partners

The main advantage of trading using opposite Eli Lilly and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eli Lilly position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.

The idea behind Eli Lilly and and Molecular Partners AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.